KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Short-term Investments (2016 - 2025)

Exact Sciences (EXAS) has disclosed Short-term Investments for 16 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 98.01% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 98.01% decrease, with the full-year FY2025 number at $8.7 million, down 98.01% from a year prior.
  • Short-term Investments was $8.7 million for Q4 2025 at Exact Sciences, down from $214.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $944.7 million in Q3 2021 to a low of $8.7 million in Q4 2025.
  • A 5-year average of $402.9 million and a median of $403.1 million in 2022 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 209.24% in 2024, then crashed 98.01% in 2025.
  • Exact Sciences' Short-term Investments stood at $715.0 million in 2021, then plummeted by 45.52% to $389.6 million in 2022, then plummeted by 55.78% to $172.3 million in 2023, then surged by 153.76% to $437.1 million in 2024, then plummeted by 98.01% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Short-term Investments are $8.7 million (Q4 2025), $214.1 million (Q3 2025), and $201.3 million (Q2 2025).